Abstract
Hypertension is traditionally considered a disease in which elevated blood pressure contributes to inflammation and activation of the immune system, leading to cardiovascular injury and end-organ damage. Here, we discuss the effects of aldosterone on the immune system and aldosterone’s contribution to vascular pathogenesis. Studies in human have suggested a broader role for aldosterone, beyond elevating blood pressure. Recent clinical data support the notion that aldosterone can directly alter the function of the immune system and cause vascular-damaging inflammation. Clinical observations have been reproduced in experimental models of hypertension, further supporting the idea that an aberrant immune response contributes to the onset of hypertension. Such studies have shown that myeloid cells are required to induce the disease and IL-17-producing CD4+ T cells may contribute to maintaining aldosterone-mediated hypertension. In addition, regulatory T cells diminish the inflammatory damage caused by aldosterone during hypertension. This is a very active area of research that could lead to new therapeutic targets for treating hypertension.
Keywords: Aldosterone, GPR30, hypertension, inflammation, mineralocorticoid receptor.
Current Molecular Medicine
Title:Immune System Alterations by Aldosterone During Hypertension: From Clinical Observations to Genomic and Non-Genomic Mechanisms Leading to Vascular Damage
Volume: 13 Issue: 6
Author(s): N. Munoz-Durango, M.F. Barake, N.A. Letelier, C. Campino, C.E. Fardella and A.M. Kalergis
Affiliation:
Keywords: Aldosterone, GPR30, hypertension, inflammation, mineralocorticoid receptor.
Abstract: Hypertension is traditionally considered a disease in which elevated blood pressure contributes to inflammation and activation of the immune system, leading to cardiovascular injury and end-organ damage. Here, we discuss the effects of aldosterone on the immune system and aldosterone’s contribution to vascular pathogenesis. Studies in human have suggested a broader role for aldosterone, beyond elevating blood pressure. Recent clinical data support the notion that aldosterone can directly alter the function of the immune system and cause vascular-damaging inflammation. Clinical observations have been reproduced in experimental models of hypertension, further supporting the idea that an aberrant immune response contributes to the onset of hypertension. Such studies have shown that myeloid cells are required to induce the disease and IL-17-producing CD4+ T cells may contribute to maintaining aldosterone-mediated hypertension. In addition, regulatory T cells diminish the inflammatory damage caused by aldosterone during hypertension. This is a very active area of research that could lead to new therapeutic targets for treating hypertension.
Export Options
About this article
Cite this article as:
Munoz-Durango N., Barake M.F., Letelier N.A., Campino C., Fardella C.E. and Kalergis A.M., Immune System Alterations by Aldosterone During Hypertension: From Clinical Observations to Genomic and Non-Genomic Mechanisms Leading to Vascular Damage, Current Molecular Medicine 2013; 13 (6) . https://dx.doi.org/10.2174/1566524011313060015
DOI https://dx.doi.org/10.2174/1566524011313060015 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
CNS & Neurological Disorders - Drug Targets The Role of Omega-3 Polyunsaturated Fatty Acids Supplementation in Childhood: A Review
Recent Patents on Cardiovascular Drug Discovery Combination of Fenofibrate with Non-Statin Drug Regimens
Current Pharmaceutical Design Carfilzomib: A Tale of a Heartbreaking Moment: Case Report and Concise Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets Blood Pressure Reduction in the Primary and Secondary Prevention of Stroke
Current Vascular Pharmacology Ghrelin and Motilin in the Gastrointestinal System
Current Pharmaceutical Design The Pharmacological Effects of Novokinin; a Designed Peptide Agonist of the Angiotensin AT<sab>2</sab> Receptor
Current Pharmaceutical Design Physical Exercise and ACE2-Angiotensin-(1-7)-Mas Receptor Axis of the Renin Angiotensin System
Protein & Peptide Letters ESVS Guidelines: Section A - Prevention in Patients with Carotid Stenosis
Current Vascular Pharmacology Best Practice for Atrial Fibrillation Patient Education
Current Pharmaceutical Design Beneficiary and Adverse Effects of Phytoestrogens: A Potential Constituent of Plant-based Diet
Current Pharmaceutical Design Safety of Dipeptidyl Peptidase 4 Inhibitors for Treatment of Type 2 Diabetes
Current Drug Safety The Role of local Insulin-like Growth Factor-1 Isoforms in the Pathophysiology of Skeletal Muscle
Current Genomics Structure Prediction of SPAK C-terminal Domain and Analysis of its Binding to RFXV/I Motifs by Homology Modelling, Docking and Molecular Dynamics Simulation Studies
Current Computer-Aided Drug Design Persistent Clinical Response of Infliximab Therapy in Patients with Refractory Rheumatoid Arthritis, over a 3-Year Period
Current Clinical Pharmacology A Model on the Induction of Adverse Vascular Long-Term Effects of NSAIDs
Medicinal Chemistry Recent Patents in Plant Biotechnology: Impact on Global Health
Recent Patents on Biotechnology Smad-Signaling in Mammary Gland Development and Tumorigenesis
Current Signal Transduction Therapy Pancreastatin, A Regulatory Peptide that Modulates Energy Metabolism
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Phenolic Compounds from Plants as Nitric Oxide Production Inhibitors
Current Medicinal Chemistry